Page 835 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

Index 813

B Bile duct tumors Blood loss anemia, 102
B cell, 148 pathology and natural behavior of, Blood smear, preparation of, 127
Blood vessel growth
455–456
Bacillus Calmette-Guerin (BCG)
VetBooks.ir noninvasive TCC and, 236 Biliary cystadenoma, 455, 456f inhibition of, 263
therapy and prognosis for, 459
use of, 236
VEGF and, 263
Bacterial infection, inoperable sarcomas and, 236 Biliary tumor, 135 Bloodroot, 333–334
Bacterial prostatitis, 633f pain caused by, 287t Body condition scoring system, 302
Bad news, delivering, 316 Bioactive eicosanoid, 308f by Purina, 303f
Basal cell carcinoma (BCC) Biologically effective dose (BED), 182–183 Body size
cytological evaluation of, 356 concept of, 214–215 cancer and, 3–4, 3f
genetic abnormalities in, 354 formula for, 214–215 observational studies for, 87t–91t
histopathologic evaluation of, 356 phase I trial and, 340–341 Body surface area (BSA), calculation formula
incidence of requirements of, 342 for, 188–189
in cats, 356 Biologic-response modifier (BRM), 24 Body weight, assessment of, 302
in dogs, 356 effects of, 24 Bolus, 215
treatment of, 356 types of Bone cysts, 553
Basal cell tumor, 355 Carrisyn (Acemannan), 24 Bone marrow disorders, canine, 735–739
fine-needle aspiration of, 132f interferons, 24 diagnostic techniques and workup,
heavily pigmented cells, 132f lymphocyte T-cell immunomodulator 736–738, 737f
trichoblastoma as, 358 as, 24 history and clinical signs, 736
Basosquamous cell carcinoma, 355–356 Biomarker myelodysplastic syndrome, 735–736
characteristics of, 356 for angiogenesis, 268 treatment, 739
Bax, expression of, 39 CEC/CEP assessment for analysis of, 268 myelofibrosis, 735
Bay12-9566, 264 goals of, 268 prognosis, 739
Bayesian adaptive design, 346–347 Biopsy treatment, 738–739
BCC. see Basal cell carcinoma definition of, 158 Bone marrow-derived cell
B-cell DLBCL, 153 endoscopic, 160–161 as metastatic, 7
B-cell lymphoma general guidelines for tissue procurement premetastatic niche modulation and, 54
gene expression profiling and, 153 and fixation of, 162–163 Bone necrosis, radiation therapy and, 374
immunohistochemical markers/panels for, image-guided, 161 Bone sarcoma, 524
72t–73t interpretation of, 163 Bone scintigraphy, 118, 119f
BCG. see Bacillus Calmette-Guerin laparoscopic and thoracoscopic, 161 Bone surface osteosarcoma, 550
Bcr-abl Philadelphia chromosome, 147 methods of, 158–162 Bone tumors
Bcr gene, 11–12 of oral tumors, 436 benign, 552–553
BED. see Biologically effective dose principles of, 158–163 bone cysts, 553
Behavior, pain and, 288, 290t sample multiple cartilaginous exostosis,
Benign adenomas, in eyelid, 675 freezing of, 61–62 552–553, 552f
Benign mammary neoplasm, 608 handling of, 61–62 osteomas, 552
Benign mesenchymal tumors, as uterine labeling of, 62 periarticular tumors, 553
tumors, 600 preservation of, 61–62 characteristics of, 140
Benign prostatic hyperplasia, 19 shipping of, 61 hemipelvectomy for, 541
Benign prostatic hypertrophy, 633 size of, 61 mandibulectomy for, 541
Benign tumor, 40 sentinel lymph node mapping and, metastatic, 552
characteristics of, 63 161–162 pain caused by, 287t
histologic features of, 65t of skin tumor, 355 primary
hyperplasia versus, 63 for soft tissue sarcoma, 410 of cats, 553–555
malignant tumor versus, 63 technique for, 158 of dogs, 550
nomenclature for, 64t incisional, 160 radiography and, 114f
types of, 63 needle core, 159 scapulectomy for, 541
Beta-cell tumors punch, 159–160 Boswellia, 332, 334
characteristics of, 137 transverse incisions for, 162 Botanical medicine, in integrative oncology,
in dogs, 582–584 Biphosphate, 100–101 331–335
Bevacizumab, side effects of, 267 Birt-Hogg-Dube (BHD) gene, 354, 600 Bowenoid carcinoma in situ (BISC), 357
Bias, in clinical trial, 344 BISC. see Bowenoid carcinoma in situ treatment of, 357
Bilateral adrenalectomy, for adrenal tumors, Bisphosphonate, 297 Bowen’s carcinoma, 357
574 Bladder cancer, acrolein exposure and, 15 Bowen’s disease, 40
Bilateral thyroid carcinomas, 576 Bladder carcinoma, cystosonography of, 648f Bowen’s in situ carcinoma, 357f
Bilateral thyroidectomy, for feline Bland embolization, 178 Brachytherapy, 215
hyperthyroidism, 579 Bleomycin, for oral melanoma, 375 Brain tumor
Bile duct adenoma, 455, 456f Blepharoplasty, for ocular tumors, 677 benign and malignant, 64t, 657
Bile duct carcinoma, 455–456, 456f Blocking checkpoint molecules, 235 in cats, 658, 658t
biologic behavior of, 456 Blood count, for intestinal tumors, 463 classification of, 657